Patient leaflet - Mozobil
1. What Mozobil is and what it is used for
Mozobil contains the active substance plerixafor which blocks a protein on the surface of blood stem cells. This protein “ties” blood stem cells to the bone marrow. Plerixafor improves the release of stem cells into the blood stream (mobilisation). The stem cells can then be collected by a machine that separates blood constituents (apheresis machine), and subsequently frozen and stored until your transplant.
If mobilisation is poor, Mozobil is used to help collect blood stem cells from the patient, for collection, storage and reintroduction (transplantation),
- In adults who have lymphoma (a cancer of the white blood cells) or multiple myeloma (a cancer that affects plasma cells in the bone marrow).
- In children age 1 to less than 18 years of age with lymphoma or solid tumours.
2. What you need to know before you use Mozobil
Do not use Mozobil
- if you are allergic to plerixafor or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor before using Mozobil.
Tell your doctor:
- if you have or have had any heart problems.
- if you have kidney problems. Your doctor may adjust the dose.
- if you have high white blood cell counts.
- if you have low platelet counts.
- if you have a history of feeling faint or lightheaded on standing or sitting or have fainted before upon injections.
Your doctor may perform regular blood tests to monitor your blood cell count.
It is not recommended to use Mozobil for stem cell mobilisation if you have leukaemia (a cancer of the blood or bone marrow).
Other medicines and Mozobil
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Pregnancy and breast-feeding
You should not use Mozobil if you are pregnant, since there is no experience with Mozobil in pregnant women. It is important to tell your doctor if you are, think you may be or are planning to become pregnant. It is recommended to use contraception if you are of child-bearing age.
You should not breast-feed if you are using Mozobil, since it is not known if Mozobil is excreted in human milk.
Driving and using machines
Mozobil may cause dizziness and fatigue. Therefore, you should avoid driving if you feel dizzy, tired or unwell.
Mozobil contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free’.
3. How to use Mozobil
Your medicine will be injected by a doctor or a nurse.
You will first receive G-CSF, then you will be given Mozobil
Mobilisation will be started by first giving you another medicine called G-CSF (granulocyte-colony stimulating factor). G-CSF will help Mozobil to work properly in your body. If you want to know more about G-CSF ask your doctor and read the corresponding package leaflet.
How much Mozobil is given?
The recommended adult dose is either a 20 mg (fixed dose) or 0.24 mg/kg body weight/day.
The recommended dose for children, 1 to less than 18 years of age is 0.24 mg/kg of body weight/day.
Your dose will depend on your body weight, which should be measured the week before you receive your first dose. If you have moderate or severe kidney problems, your doctor will reduce the dose.
How is Mozobil given?
Mozobil is given by subcutaneous injection (under your skin).
When is Mozobil given for the first time?
You will receive your first dose 6 to 11 hours before apheresis (collection of your blood stem cells).
How long will Mozobil be given?
Treatment lasts 2 to 4 consecutive days (in some cases up to 7 days), until enough stem cells have been collected for your transplant. In a few cases, enough stem cells may not be collected, and the collection attempt will be stopped.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Please tell your doctor immediately if
- shortly after receiving Mozobil, you experience rash, swelling around the eyes, shortness of breath or lack of oxygen, feeling lightheaded on standing or sitting, feeling faint or fainting
- you have pain in the upper left abdomen (belly) or your left shoulder
Very common side effects (may affect more than 1 in 10 people)
- diarrhoea, nausea (feeling sick), injection site redness or irritation
- low red blood cell count by laboratory test (anaemia in children)
Common side effects (may affect up to 1 in 10 people)
- headache
- dizziness, feeling tired or unwell
- difficulty in sleeping
- flatulence, constipation, indigestion, vomiting
- stomach symptoms such as pain, swelling or discomfort
- dry mouth, numbness around the mouth
- sweating, generalised redness of the skin, joint pains, pains in muscles and bones
Uncommon side effects (may affect up to 1 in 100 people)
- allergic reactions such as skin rash, swelling around the eyes, shortness of breath
- anaphylactic reactions, including anaphylactic shock
- abnormal dreams, nightmares
Rarely, gastrointestinal side effects may be severe (diarrhoea, vomiting, stomach pain and nausea).
Heart attacks
In clinical trials, patients with risk factors for a heart attack uncommonly suffered heart attacks after being given Mozobil and G-CSF. Please inform your doctor immediately if you experience chest discomfort.
Pins and needles and numbness
Pins and needles and numbness are common in patients being treated for cancers. About one in five patients suffered from these feelings. However, these effects do not seem to occur more frequently when you use Mozobil.
You may also have an increase in white blood cells count (leucocytosis), in your blood tests.
Reporting of side effects
If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in By reporting side effects you can help provide more information on the safety of this medicine.
5. How to store Mozobil
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and vial.
This medicine does not require any special storage conditions.
After opening the vial, Mozobil should be used immediately.
Do not throw away any medicines via wastewater or household waste. The pharmacist will throw away medicines you no longer use. These measures will help protect the environment.
6.
Contents of the pack and other information
What Mozobil contains
-
– The active substance is plerixafor. Each ml solution for injection contains 20 mg plerixafor. Each vial contains 24 mg plerixafor in 1.2 ml solution.
-
– The other ingredients are sodium chloride, hydrochloric acid (concentrated) and sodium hydroxide for pH adjustment and water for injections.
What Mozobil looks like and contents of the pack
Mozobil is supplied as a clear colourless or pale yellow solution for injection in a glass vial with a non-latex rubber stopper. Each vial contains 1.2 ml solution.
Each pack contains 1 vial.
Marketing Authorisation Holder
Genzyme Europe B.V.
Paasheuvelweg 25
1105 BP Amsterdam
The Netherlands.
Manufacturer
Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
| België/Belgique/Belgien/ Luxembourg/Luxemburg Sanofi Belgium | Lietuva Swixx Biopharma UAB Tel. +370 5 236 91 40 |
Tél/Tel: + 32 2 710 54 00
| Efc^rapufl Swixx Biopharma EOOD Ten: +359 (0)2 4942 480 | Magyarország SANOFI-AVENTIS Zrt. Tel: +36 1 505 0050 |
| Česká republika sanofi-aventis, s.r.o. Tel: +420 233 086 111 | Malta Sanofi S.r.l. Tel: +39 02 39394275 |
| Danmark sanofi A/S Tlf: +45 45 16 70 00 | Nederland Genzyme Europe B.V. Tel: +31 20 245 4000 |
| Deutschland Sanofi-Aventis Deutschland GmbH Tel: +49 (0)180 2 222010 | Norge sanofi-aventis Norge AS Tlf: + 47 67 10 71 00 |
| Eesti Swixx Biopharma OÜ Tel. +372 640 10 30 | Österreich sanofi-aventis GmbH Tel: + 43 1 80 185 – 0 |
| EXÀàôa sanofi-aventis AEBE Tql: +30 210 900 1600 | Polska sanofi-aventis Sp. z o.o. Tel.: +48 22 280 00 00 |
| España sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Portugal Sanofi – Produtos Farmacéuticos, Lda. Tel: +351 21 35 89 400 |
| France sanofi-aventis France Tél : 0 800 222 555 Appel depuis l’étranger : +33 1 57 63 23 23 | Romania Sanofi Romania SRL Tel: +40 (0) 21 317 31 36 |
| Hrvatska Swixx Biopharma d.o.o. Tel: +385 1 2078 500 | Slovenija Swixx Biopharma d.o.o. Tel: +386 1 235 51 00 |
| Ireland sanofi-aventis Ireland Ltd T/A SANOFI Tel: +353 (0) 1 4035 600 | Slovenská republika Swixx Biopharma s.r.o. Tel.: +421 2 208 33 600 |
| Ísland Vistor hf. Sími: +354 535 7000 | Suomi/Finland Sanofi Oy Puh/Tel: + 358 201 200 300 |
| Italia Sanofi S.r.l. Tel: 800536389 | Sverige Sanofi AB Tel: +46 (0)8 634 50 00 |
Latvija
Swixx Biopharma SIA
Tel: +371 6 616 47 50
United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525
Kûnpoç
C.A. Papaellinas Ltd.
Tql: +357 22 741741
This leaflet was last approved in.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
28